0 citations
HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
Journal of the Neurological Sciences2021Vol. 429, pp. 117767–117767
Citations Over Time
Davide Adams, Ivailo Tournev, Mark Taylor, Teresa Coelho, Violaine Planté‐Bordeneuve, John L. Berk, Alejandra González‐Duarte, Julian D. Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Obici, Rick E. Blakesley, Seth Arum, Rebecca A. Shilling, Joshua R. Vest, Michael Polydefkis
Related Papers
- → HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY(2022)8 cited
- → Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant(2018)4 cited
- → Structurally abnormal transthyretin causing familial amyloidotic polyneuropathy in Sweden(1987)28 cited
- → Aged onset of amyloidosis caused by transthyretin gene mutations(2003)
- → Neuropathological features in familial amyloid polyneuropathy caused by transthyretin E61K variant(2017)